Cytotoxic T lymphocyte responses against melanocytes and melanoma

详细信息    查看全文

• 作者：Gwendolen Y Chang (1)
  Holbrook E Kohrt (1)
  Tor B Stuge (1)
  Erich J Schwartz (2)
  Jeffrey S Weber (3)
  Peter P Lee (1)
  
• 刊名：Journal of Translational Medicine
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：9
• 期：1
• 全文大小：1615KB
• 参考文献：1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb茅 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. / N Engl J Med 2010, 363:711鈥?23. CrossRef
  2. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. / J Clin Oncol 2008, 26:5233鈥?239. CrossRef
  3. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. / J Exp Med 2000, 192:1637鈥?644. CrossRef
  4. Garbelli S, Mantovani S, Palermo B, Giachino C: Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? / Pigment Cell Res 2005, 18:234鈥?42. CrossRef
  5. Wankowicz-Kalinska A, Le Poole C, van den Wijngaard R, Storkus WJ, Das PK: Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin? / Pigment Cell Res 2003, 16:254鈥?60. CrossRef
  6. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP: Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. / Proc Natl Acad Sci USA 2008, 105:8061鈥?066. CrossRef
  7. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM: Autoimmunity and treatment outcome in melanoma. / Curr Opin Oncol 2011, 23:170鈥?76. CrossRef
  8. Rosenberg SA, Kawakami Y, Robbins PF, Wang R: Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. / Adv Cancer Res 1996, 70:145鈥?77. CrossRef
  9. Boon T: Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. / Int J Cancer 1993, 54:177鈥?80. CrossRef
  10. Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA: The use of melanosomal proteins in the immunotherapy of melanoma. / J Immunother 1998, 21:237鈥?46. CrossRef
  11. Okamoto T, Irie RF, Fujii S, Huang SK, Nizze AJ, Morton DL, Hoon DS: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. / J Invest Dermatol 1998, 111:1034鈥?039. CrossRef
  12. Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN: Immunity to cancer through immune recognition of altered self: studies with melanoma. / Adv Cancer Res 2003, 90:157鈥?77. CrossRef
  13. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. / J Immunol 1998, 160:643鈥?51.
  14. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. / J Immunol Methods 2003, 281:65鈥?8. CrossRef
  15. Kohrt HE, Shu CT, Stuge TB, Holmes SP, Weber J, Lee PP: Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. / J Immunother 2005, 28:297鈥?05. CrossRef
  16. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. / Nat Med 2003, 9:1377鈥?382. CrossRef
  17. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP: Diversity and recognition efficiency of T cell responses to cancer. / PLoS Med 2004, 1:e28. CrossRef
  18. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. / Anal Biochem 1987, 162:156鈥?59. CrossRef
  19. Jungbluth AA, Iversen K, Coplan K, Williamson B, Chen YT, Stockert E, Old LJ, Busam KJ: Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis. / Virchows Arch 1999, 434:429鈥?35. CrossRef
  20. Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L: Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. / Cancer Res 2003, 63:1560鈥?567.
  21. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. / J Immunol 1999, 162:2227鈥?234.
  22. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, / et al.: Prognostic significance of autoimmunity during treatment of melanoma with interferon. / N Engl J Med 2006, 354:709鈥?18. CrossRef
  23. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB: Vitiligo in patients with metastatic melanoma: a good prognostic sign. / J Am Acad Dermatol 1983, 9:689鈥?96. CrossRef
  24. Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic significance of hypopigmentation in malignant melanoma. / Arch Dermatol 1987, 123:1053鈥?055. CrossRef
  25. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. / J Invest Dermatol 2006, 126:2658鈥?663. CrossRef
  26. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG: Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. / J Invest Dermatol 2001, 117:1464鈥?470. CrossRef
  27. Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. / Proc Natl Acad Sci USA 2001, 98:10302鈥?0307. CrossRef
  28. Schallreuter KU, Levenig C, Berger J: Vitiligo and cutaneous melanoma. A case study. / Dermatologica 1991, 183:239鈥?45. CrossRef
  29. Steitz J, Bruck J, Lenz J, Buchs S, Tuting T: Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo. / J Invest Dermatol 2005, 124:144鈥?50. CrossRef
  30. Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ, Hoogerbrugge PM, Figdor CG, Adema GJ, Punt CJ, de Vries IJ: Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. / Cancer Immunol Immunother 2009, 58:145鈥?51. CrossRef
  31. Rivoltini L, Barracchini KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA, Marincola FM: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. / Cancer Res 1995, 55:3149鈥?157.
  32. Lethe B, van der Bruggen P, Brasseur F, Boon T: MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. / Melanoma Res 1997,7(Suppl 2):S83鈥?8.
  33. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA, Marincola FM: Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. / Int J Cancer 2000, 86:818鈥?26. CrossRef
  34. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J: Tumor antigen expression in melanoma varies according to antigen and stage. / Clin Cancer Res 2006, 12:764鈥?71. CrossRef
  35. Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, Dummer R: Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. / Melanoma Res 2004, 14:257鈥?62. CrossRef
  36. Urosevic M, Braun B, Willers J, Burg G, Dummer R: Expression of melanoma-associated antigens in melanoma cell cultures. / Exp Dermatol 2005, 14:491鈥?97. CrossRef
  37. Khong HT, Wang QJ, Rosenberg SA: Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. / J Immunother 2004, 27:184鈥?90. CrossRef
  38. Durda PJ, Dunn IS, Rose LB, Butera D, Benson EM, Pandolfi F, Kurnick JT: Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression. / Mol Cancer Res 2003, 1:411鈥?19.
  39. Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ: A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. / J Immunol 2001, 167:1204鈥?211.
  40. Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A, Lotze MT: Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. / Clin Cancer Res 1996, 2:641鈥?52.
  
• 作者单位：Gwendolen Y Chang (1)
  Holbrook E Kohrt (1)
  Tor B Stuge (1)
  Erich J Schwartz (2)
  Jeffrey S Weber (3)
  Peter P Lee (1)
  
  1. Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, California, USA
  2. Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
  3. Moffitt Cancer Center, Tampa, Florida, USA
  

文摘

Background Vitiligo is a common toxicity associated with immunotherapy for melanoma. Cytotoxic T lymphocytes (CTLs) against melanoma commonly target melanoma-associated antigens (MAAs) which are also expressed by melanocytes. To uncouple vitiligo from melanoma destruction, it is important to understand if CTLs can respond against melanoma and melanocytes at different levels. Methods To understand the dichotomous role of MAA-specific CTL, we characterized the functional reactivities of established CTL clones directed to MAAs against melanoma and melanocyte cell lines. Results CTL clones generated from melanoma patients were capable of eliciting MHC-restricted, MAA-specific lysis against melanocyte cell lines as well as melanoma cells. Among the tested HLA-A*0201-restricted CTL clones, melanocytes evoked equal to slightly higher degranulation and cytolytic responses as compared to melanoma cells. Moreover, MAA-specific T cells from vaccinated patients responded directly ex vivo to melanoma and melanocytes. Melanoma cells express slightly higher levels of MART-1 and gp100 than melanocytes as measured by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and immunohistochemistry. Conclusions Our data suggest that CTLs respond to melanoma and melanocytes equally in vitro and directly ex vivo.